Data from early-phase studies of tamibarotene in combination with AZA in AML patients with RARα overexpression appeared positive [177], but trials of tamibarotene in both higher-risk MDS and AML were later terminated due to the lack of benefit found in subsequent analyses. The gene discussed is RARA; the disease is myelodysplastic syndrome.